对于某些Ⅲc期至Ⅳ期卵巢癌患者，新辅助化疗是更好的治疗选择。 - Suppr

Suppr

超能文献

Neoadjuvant chemotherapy is the better treatment option in some patients with stage IIIc to IV ovarian cancer.

作者信息

Vergote Ignace, Tropé Claes G, Amant Frédéric, Ehlen Tom, Reed Nick S, Casado Antonio

机构信息

University Hospitals Leuven, Leuven, Belgium.

出版信息

J Clin Oncol. 2011 Nov 1;29(31):4076-8. doi: 10.1200/JCO.2011.36.9785. Epub 2011 Sep 19.

DOI:10.1200/JCO.2011.36.9785

PMID:21931032

Abstract

摘要

相似文献

Neoadjuvant chemotherapy is the better treatment option in some patients with stage IIIc to IV ovarian cancer.对于某些Ⅲc期至Ⅳ期卵巢癌患者，新辅助化疗是更好的治疗选择。

J Clin Oncol. 2011 Nov 1;29(31):4076-8. doi: 10.1200/JCO.2011.36.9785. Epub 2011 Sep 19.

Neoadjuvant chemotherapy is rarely the easy way out.新辅助化疗很少是一条轻松的出路。

J Clin Oncol. 2012 May 1;30(13):1563; author reply 1563-4. doi: 10.1200/JCO.2011.40.8401. Epub 2012 Mar 12.

Is the easier way ever the better way?更容易的方法就永远是更好的方法吗？

J Clin Oncol. 2011 Nov 1;29(31):4073-5. doi: 10.1200/JCO.2011.35.9935. Epub 2011 Sep 19.

Primary surgery or neoadjuvant chemotherapy followed by interval debulking surgery in advanced ovarian cancer.晚期卵巢癌行初次肿瘤细胞减灭术或新辅助化疗后间隔减瘤术。

Eur J Cancer. 2011 Sep;47 Suppl 3:S88-92. doi: 10.1016/S0959-8049(11)70152-6.

Which patients benefit most from primary surgery or neoadjuvant chemotherapy in stage IIIC or IV ovarian cancer? An exploratory analysis of the European Organisation for Research and Treatment of Cancer 55971 randomised trial.哪些 IIIC 期或 IV 期卵巢癌患者最受益于初始手术或新辅助化疗？欧洲癌症研究与治疗组织 55971 随机试验的探索性分析。

Eur J Cancer. 2013 Oct;49(15):3191-201. doi: 10.1016/j.ejca.2013.06.013. Epub 2013 Jul 11.

[Neoadjuvant chemotherapy in the treatment of ovarian cancer].[新辅助化疗在卵巢癌治疗中的应用]

Orv Hetil. 2005 Sep 18;146(38):1951-5.

Role of neoadjuvant chemotherapy in the management of stage IIIC-IV ovarian cancer: survey results from the members of the European Society of Gynecological Oncology.新辅助化疗在 IIIC-IV 期卵巢癌治疗中的作用：欧洲妇科肿瘤学会成员的调查结果。

Int J Gynecol Cancer. 2012 Mar;22(3):407-16. doi: 10.1097/IGC.0b013e31823ea1d8.

[Impact of neoadjuvant chemotherapy on the survival of patients with stage IIIc and IV epithelial ovarian cancer].新辅助化疗对Ⅲc期和Ⅳ期上皮性卵巢癌患者生存的影响

Zhonghua Zhong Liu Za Zhi. 2008 Apr;30(4):298-301.

Survival outcomes after extensive cytoreductive surgery and selective neoadjuvant chemotherapy according to institutional criteria in bulky stage IIIC and IV epithelial ovarian cancer.根据机构标准，对晚期IIIC期和IV期上皮性卵巢癌进行广泛细胞减灭术和选择性新辅助化疗后的生存结果。

J Gynecol Oncol. 2017 Jul;28(4):e48. doi: 10.3802/jgo.2017.28.e48.

Neoadjuvant chemotherapy for advanced ovarian cancer: overview of outcomes and unanswered questions.晚期卵巢癌的新辅助化疗：结局概述及未解决的问题。

Expert Rev Anticancer Ther. 2011 Jul;11(7):1053-67. doi: 10.1586/era.11.24.

引用本文的文献

Neoadjuvant chemotherapy before surgery versus surgery followed by chemotherapy for initial treatment in advanced epithelial ovarian cancer.晚期上皮性卵巢癌初始治疗中，术前新辅助化疗与手术加化疗的比较。

Cochrane Database Syst Rev. 2025 Feb 10;2(2):CD005343. doi: 10.1002/14651858.CD005343.pub7.

5-Hydroxymethylcytosine signals in serum are a predictor of chemoresistance in high-grade serous ovarian cancer.血清中的 5-羟甲基胞嘧啶信号是预测高级别浆液性卵巢癌化疗耐药的标志物。

Gynecol Oncol. 2024 Mar;182:82-90. doi: 10.1016/j.ygyno.2024.01.001. Epub 2024 Jan 22.

Impact of residual disease as a prognostic factor for survival in women with advanced epithelial ovarian cancer after primary surgery.原发性手术后晚期上皮性卵巢癌患者残留病灶对生存预后的影响。

Cochrane Database Syst Rev. 2022 Sep 26;9(9):CD015048. doi: 10.1002/14651858.CD015048.pub2.

Neoadjuvant chemotherapy before surgery versus surgery followed by chemotherapy for initial treatment in advanced ovarian epithelial cancer.新辅助化疗在手术前与手术后化疗用于晚期卵巢上皮癌的初始治疗。

Cochrane Database Syst Rev. 2021 Jul 30;7(7):CD005343. doi: 10.1002/14651858.CD005343.pub6.

GEN-1 in Combination with Neoadjuvant Chemotherapy for Patients with Advanced Epithelial Ovarian Cancer: A Phase I Dose-escalation Study.GEN-1 联合新辅助化疗治疗晚期上皮性卵巢癌患者：一项 I 期剂量递增研究。

Clin Cancer Res. 2021 Oct 15;27(20):5536-5545. doi: 10.1158/1078-0432.CCR-21-0360. Epub 2021 Jul 29.

Chemotherapy versus surgery for initial treatment in advanced ovarian epithelial cancer.晚期卵巢上皮癌初始治疗中化疗与手术的比较

Cochrane Database Syst Rev. 2021 Feb 5;2(2):CD005343. doi: 10.1002/14651858.CD005343.pub5.

Comparing Paclitaxel-Carboplatin with Paclitaxel-Cisplatin as the Front-Line Chemotherapy for Patients with FIGO IIIC Serous-Type Tubo-Ovarian Cancer.比较紫杉醇-卡铂与紫杉醇-顺铂作为FIGO III C 期浆液性卵巢癌患者的一线化疗方案。

Int J Environ Res Public Health. 2020 Mar 26;17(7):2213. doi: 10.3390/ijerph17072213.

Chemotherapy versus surgery for initial treatment in advanced ovarian epithelial cancer.晚期卵巢上皮癌初始治疗中化疗与手术的比较

Cochrane Database Syst Rev. 2019 Oct 31;2019(10):CD005343. doi: 10.1002/14651858.CD005343.pub4.

Tumor evolution and chemoresistance in ovarian cancer.卵巢癌中的肿瘤演变与化疗耐药性

NPJ Precis Oncol. 2018 Sep 17;2:20. doi: 10.1038/s41698-018-0063-0. eCollection 2018.

Review of methodological challenges in comparing the effectiveness of neoadjuvant chemotherapy versus primary debulking surgery for advanced ovarian cancer in the United States.美国晚期卵巢癌新辅助化疗与初次肿瘤细胞减灭术疗效比较中的方法学挑战综述

Cancer Epidemiol. 2018 Aug;55:8-16. doi: 10.1016/j.canep.2018.05.003. Epub 2018 May 25.

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验